LeMeDISCO: A computational method for large-scale prediction & molecular interpretation of disease comorbidity

Courtney Astore^{1,□}, Hongyi Zhou^{1,□}, and Jeffrey Skolnick^{*,1}

¹Center for the Study of Systems Biology, School of Biological Sciences, Georgia Institute of
Technology, Atlanta, GA, 30332, USA

^{*}skolnick@gatech.edu

□These authors contributed equally to this work

Abstract

Often different diseases tend to co-occur (i.e., they are comorbid), which yields the question: what is the molecular basis of their coincidence? Perhaps, common proteins are comorbid disease drivers. To understand the origin of disease comorbidity and to identify the essential proteins and pathways underlying comorbid diseases, we developed **LeMeDISCO** (Large-Scale Molecular Interpretation of Disease Comorbidity), an algorithm that predicts disease comorbidities from shared mode of action (MOA) proteins predicted by the AI-based **MEDICASCY** algorithm. **LeMeDISCO** was applied to predict the general occurrence of comorbid diseases for 3608 distinct diseases. To illustrate **LeMeDISCO**'s power, we elucidate the possible etiology of coronary artery disease and ovarian cancer by determining the comorbidity enriched MOA proteins and pathways and suggest hypotheses for subsequent scientific investigation. The **LeMeDISCO** web server is available for academic users at: <http://sites.gatech.edu/cssb/LeMeDISCO>.

Introduction

Disease comorbidity, the cooccurrence of distinct diseases is an interesting medical phenomenon. For example, individuals having one autoimmune condition likely develop another. Interestingly, rheumatoid arthritis, autoimmune thyroiditis, and insulin-dependent diabetes mellitus cooccur, but rheumatoid arthritis and multiple sclerosis do not¹. Previously, there have been several efforts to investigate the molecular features responsible for human disease comorbidities²⁻⁸. Some studies focused on particular subsets of diseases³ or ethnic groups, while others investigated the entire human disease network⁴⁻⁷. For example, Zhou et. al.⁵ applied text mining to search the literature for disease-symptom associations. They then predicted the entire human disease-disease network based on a calculated symptom similarity score. While this approach covers almost all human diseases, it only explains one phenotype (disease) by another phenotype (symptom). Menche *et. al.*⁶ utilized known disease-gene associations from GWAS⁹ and OMIM combined with a protein-protein interaction network to identify connected disease gene clusters or modules. Another study also utilized known disease-gene associations and protein-protein interaction networks to characterize disease-disease relationships without requiring gene clusters⁷; thus, its disease coverage is better than in ref.⁶. A deeper analysis of these studies, which have low recall rates, demonstrates that focusing entirely on shared genes is insufficient to predict disease comorbidity or identify its origins. They miss collective effects arising from both direct and indirect protein-protein interactions and pathway correlations.

Existing studies that use known disease-gene associations are limited by data availability. Indeed, only a small fraction of diseases has known associated genes. For example, ref.⁷ only covers 1,022 of the 8,043 diseases in the Disease Ontology database¹⁰, with just 6,594 pairs of diseases having a non-zero number of shared genes. Similarly, ref.⁶ found that most (59%) of their 44,551 disease pairs do not share any genes. To address these limitations, we developed **LeMeDISCO** which extends our recently developed **MEDICASCY** machine learning approach¹¹ for predicting disease indications and mode of action (MOA) proteins (as well as small molecule drug side effects and efficacy) to predict disease

comorbidities and the proteins and pathways responsible for their comorbidity. We then show that **LeMeDISCO** covers a broader spectrum of comorbid diseases than existing approaches. Assuming that the most enriched comorbid proteins are responsible for disease comorbidity, we determine the most frequent comorbidity enriched MOA proteins. These proteins are then employed in pathway analysis¹². As examples, we predict the comorbid diseases, comorbidity enriched MOA proteins, and pathways associated with coronary artery disease (CAD) and ovarian cancer (OC).

Results

Benchmarking Results of LeMeDISCO

To assess its relative performance, we compared the results of **LeMeDISCO** to three other methods, the XD score⁷, the S_{AB} score and the Symptom Similarity score⁵. Table 1 summarizes the results. We define a positive comorbidity pair when their $\log(RR) > 0$, XD score > 0 , S_{AB} score < 0 , or the symptom similarity score > 0.1 ¹³ and p-value < 0.05 for J-score. The relative risk RR is defined in eq. 4a and is the probability that two diseases occur in a single individual relative to random. The ϕ -score is the Pearson's correlation for binary variables and is defined in eq. 4b. Mapping the DOIDs from the Human Disease Ontology database to the ICD-9 IDs of ref.¹⁴, we obtain 198,149 disease pairs for use in **LeMeDISCO** benchmarking. All correlations of the J-score with the $\log(RR)$ score and ϕ -score are statistically significant (p-value < 0.05).

To compare **LeMeDISCO** to the XD score, we mapped their ICD-9 disease code to the DOIDs and obtained a subset of 29,783 pairs from their dataset of 97,665 pairs⁷. As shown in Figure S1, their NG score (the number of shared genes) essentially has no significant correlation with $\log(RR)$ and only shows a correlation with the ϕ -score for unbinned data. When the data are binned, both the XD score and NG score lack significant correlations. J-score has much better correlations and recall rate than XD score.

For comparison with the S_{AB} score⁶, the MeSH¹⁵ disease names¹⁶ were mapped to their DOIDs. A consensus set of 947 disease pairs from their dataset and ours was obtained. As shown in Figure S2 and

Table 1, compared to S_{AB} ⁶, for the 947 disease pairs, **LeMeDISCO**'s J-score is better than the S_{AB} score for both unbinned and binned data, and it has a much better recall rate than the S_{AB} score. The S_{AB} score has no significant correlation for the binned ϕ -score data. The reason for the worse performance of S_{AB} for binned data is as follows: unbinned data for S_{AB} are dominated by cases where no disease comorbidity is predicted ($S_{AB}>0$), whereas for binned data, both $S_{AB}<0$ and $S_{AB}>0$ is important.

Next, a common dataset of 2,630 disease pairs was obtained for comparison with the symptom similarity score. As shown in Figure S3, the symptom similarity score has a better correlation than **LeMeDISCO** for the log(RR) and is almost identical to the ϕ -score for unbinned data. However, the symptom similarity score only explains the relationship of one phenotype (symptom) to another phenotype (disease). Nevertheless, all correlations of the J-score are statistically significant, and its recall rate is close to 70%.

The advantage of the J-score over the symptom similarity score is that it has a clear molecular interpretation. Moreover, **LeMeDISCO** does not rely on prior knowledge or symptomatic information. Hence, it provides a much larger coverage of comorbidity predictions for the 198,149 disease pairs, each ranked by its J-score and the corresponding p-value to reflect the statistical significance. The correlation of the J-score and the log(RR) and ϕ -score for this large set of disease pairs is shown in Figure S4.

MEDICASCY based MOA protein prediction

The ICD-10 main classification coverage of the 3,608 diseases is shown in Figure 1A. We first examine the number of predicted MOA proteins per indication from **MEDICASCY**¹¹. Using a p-value cutoff of 0.05 and including protein isoforms, the average (median) number of MOA proteins per indication is 1,744.5 (656); the maximal and minimal values are 17,324 (almost half of the total 32,584 screened proteins) for mast cell sarcoma and 0 for esophageal atresia. The histogram of the number of MOAs is shown in Figure 1B. 68.0% (41.1%) of indications have > 500 (1,000) MOA proteins; several are likely false positives or have a minor contribution to the disease, at best. However, these associations allow us to expand the protein repertoire that might be associated with each disease and are like the

statistics from GWAS studies. Below, we describe the use of **LeMeDISCO** to predict disease comorbidities as well as prioritize these proteins.

Shared MOA proteins explain disease comorbidity by way of disease-disease relationships

We next examine the overall characteristics of the predicted comorbidity network of 3,608 diseases. There are a total of 6,508,832 possible pairwise disease associations. From this, there are 5,987,682 significant pairwise disease associations excluding the diagonals and 3,009,095 significant non-redundant pairwise disease associations given by **LeMeDISCO**. Only one disease, esophageal atresia, did not have any significant comorbidities predicted. Thus, 3,607 diseases contained significant comorbidities ($p\text{-value} < 0.05$). The density and frequency of the J-score for the significant pairs is in Figure 1C, and the density and frequency of the degree (number of edges) for each node (disease) is represented in Figure 1D. Using a $p\text{-value}$ cutoff of 0.05, the average (median) number of comorbidities per disease is 1,650.7 (1806). The largest (smallest) number of comorbidities is 2,958 for gastric mucosal hypertrophy (17 for Canavan disease). Thus, the disease network is very dense.

The cumulative distribution for the J-score and $p\text{-values}$ for all of the comorbidities and the top 100 are shown in Figure S5 and S6, respectively. The summary statistics of the scores for these thresholds are shown in Table S1. What is clear from these figures and Table S1, particularly for the top 100 ranked comorbidities, is that the 98.5% top ranked 100 comorbidities have a $p\text{-value} < 0.005$. In other words, while a $p\text{-value}$ threshold of 0.05 is used, in reality the actual $p\text{-values}$ employed for subsequent analysis are far more significant.

Around 46% of the disease pairs have a $p\text{-value} < 0.05$. This result is consistent with the ~50% recall of large scale benchmarking (see Table 1) and the observed comorbidity from Medicare insurance claim data that 78.8% of the total 3,634,744 disease pairs have an $RR > 1^{14}$. As shown in Figure 1E, the giant component (GP) of the disease-disease network covers the entire network when the J-score is < 0.1 and the $p\text{-value} < 0.05$, i.e., starting from any disease, one can walk to any other disease on the network. As the J-score cutoff increases, the number of diseases in the giant component decreases; however, the

decrease is very slow. The rapid decrease only happens around a 0.45 J-score corresponding to an average p-value $\sim 3.6 \times 10^{-30}$. Thus, the disease network is not only dense, but it is also strongly and highly significantly connected.

LeMeDISCO identified MOA proteins

In addition to the comorbidity predictions, **LeMeDISCO** also identifies comorbidity enriched MOA proteins. The comorbidity enriched MOA proteins are hierarchically ranked by their CoMOAenrich score (defined in the Methods section). Comparing the top 100 comorbidity enriched MOA proteins (hierarchically ranked by the CoMOAenrich score) with the **MEDICASCY** top 100 MOA proteins (ranked by p-value), 88% of the diseases have proteins with a significant overlap p-value. The cumulative distribution for the CoMOAenrich scores and p-values for all the comorbidity enriched MOA proteins and the top 100 are shown in Figures S7 and S8, respectively. The summary statistics of the scores for these thresholds are shown in Table S1. For the comorbidity enriched MOA proteins ranked by their CoMOAenrich score, 58% have a p-value < 0.05 . However, if one only assesses the top 100 comorbidity enriched MOA proteins, 94% have a p-value < 0.05 , which are the proteins used for the global pathway analysis. Of the top 100 proteins used for pathway analysis, 82% have a p-value < 0.005 .

Mapping of the LeMeDISCO MOA proteins to significant pathways

The cumulative distribution of the p-values for the pathways and the top 100 are shown in Figure S9 and the summary statistics are provided in Table S1. As shown in Figure S9, 62% of the pathways have a p-value < 0.015 . We further note that there are some MOA proteins (e.g., SF3B1, BTAF1, and FAM160A1) and pathways (e.g., the nuclear receptor transcription pathway, SUMOylation of intracellular receptors, and PP2A-mediated dephosphorylation of key metabolic factors) that are enriched in approximately a third of the diseases in our library. This implies that there are homogenous molecular features across a subset of complex diseases. This has significant implications to disease interrelationships that will be explored elsewhere.

Applications of LeMeDISCO

By way of illustration, we applied **LeMeDISCO** to two disparate diseases, coronary artery disease (CAD) and ovarian cancer (OC).

Coronary artery disease (CAD)

CAD, a leading cause of death worldwide, is caused by narrowed or blocked arteries due to plaques composed of cholesterol or other fatty deposits lining the inner wall of the artery. These plaques result in decreased blood supply to the heart¹⁷. We find 2,747 significant comorbid diseases (p-value < 0.05), 1,459 comorbidity enriched MOA proteins (score > 0.01, meaning that at least one of the top 100 comorbid disease shares the protein as a MOA protein. This is the p-value weighted comorbidity frequency normalized by the number of comorbid diseases used for calculating the frequency. See Methods for more details. 7 significant pathways are associated with the top ranked 100 proteins (p-value < 0.05). The top 20 disease comorbidities, top 20 comorbidity enriched MOA proteins, and top 20 significant pathways are shown in Table 2. There are several cardiovascular-related significant comorbidities such as cardiovascular system disease, and myocardial infarction. Kidney disease, diabetes, obstructive lung disease and Alzheimer's disease are also in the top ten with known comorbidities to CAD. Furthermore meta-analysis indicates an association between CAD and asthma, particularly in females with adult-onset asthma¹⁹. Prostanoid ligand receptors is the third most significant pathway found for CAD, which may be due to the number of COX-related comorbidity enriched proteins found. COX are involved in the synthesis of prostanoids. Prostanoids are structurally like lipids and are involved in thrombosis and other undesirable cardiovascular events²⁰. CAD is also known to be comorbid with proteinuria, Alport syndrome, glomerulonephritis, liver disease and mitral valve insufficiency.

The above results were obtained without any extrinsic knowledge of CAD. Next, we show how additional information can be used. A GWAS study identified 155 CAD associated genes²¹. These GWAS genes associated with CAD were then used as input to GWAS-driven **LeMeDISCO**. The top 20 disease

comorbidities, top 20 comorbidity enriched MOA proteins, and top 20 pathways are shown in Table 3. There were 136 predicted significant comorbidities ($p\text{-value} < 0.05$) by **LeMeDISCO**. There were 3,039 comorbidity enriched MOA proteins ($\text{score} > 0.01$) and 57 significant pathways ($p\text{-value} < 0.05$) found from global pathway analysis of the top 100 comorbidity enriched MOA proteins. The top comorbidities are anuria and renal artery disease, both associated with dysfunction of the kidneys. Anuria is attributed to failure of the kidneys to produce urine, and renal artery disease occurs when the arteries that supply blood and oxygen to the kidneys narrows. A study found an increase in renal artery stenosis in patients with CAD²². Other diseases that have at least some literature evidence of comorbidity with CAD are leukopenia, leukocyte disease, hereditary hemorrhagic telangiectasia, recurrent hypersomnia, lactic acidosis and possibly dilated cardiomyopathy. We were unable to find a link in the literature between CAD and skin hemangioma, plasma cell neoplasm, Xeroderma pigmentosum.

ZMYM6, the top comorbidity enriched MOA protein, is highly enriched in the heart, skeletal muscle, kidney and liver, which is reflected in the type of disease comorbidities predicted. Further, there are two tropomyosin receptor kinase A (TRKA)-related pathways found via pathway analysis, activation of TRKA receptors and TRKA activation by nerve growth factor (NGF), a neurotrophin. Neurotrophins and their receptors (i.e. TRK) are known to have essential cardiovascular functions and may be suitable therapeutic targets²³. With a $\text{score} > 0.01$, there are 1,459 and 3,039 comorbidity enriched MOA proteins from the **MEDICASCY** and GWAS-driven results, respectively. From this, 212 MOA proteins overlap, yielding a significant $p\text{-value}$ ($p\text{-value} < 0.0001$). Thus, there is a significant overlap $p\text{-value}$ from the GWAS driven **LeMeDISCO** results to the **MEDICASCY** MOA protein driven **LeMeDISCO** results for the predicted MOA proteins. **LeMeDISCO** does prioritize the most putatively important ones.

Ovarian cancer (OC)

LeMeDISCO predicts 1,896 significant comorbidities to OC ($p\text{-value} < 0.05$), with 2,949 comorbidity enriched MOA proteins ($\text{score} > 0.01$). There were 67 significant pathways ($p\text{-value} < 0.05$) from the top 100 comorbidity enriched MOA proteins. The top 20 disease comorbidities, top 20 comorbidity enriched

MOA proteins, and all significant pathways are shown in Table 4. The top comorbid disease associated with OC is thyroid gland cancer. Studies have found that OC can metastasize to the thyroid gland. There are several other high confidence cancers predicted to be comorbid with OC. Colorectal cancer and OC cooccur, and there have been a limited number of examples of cooccurrence of esophageal and pancreatic cancer with OC. OC from lung cancer metastasis occurs in <4% of OC patients. OC is found to be comorbid with stomach cancer and colon cancer, as are fallopian tube cancer and OC. Bile duct cancer is a very rare site of OC metastases. Metastatic OC spreads to the liver. Peritoneal cancer behaves similarly to OC. We were unable to find any literature support for the comorbidity of OC and urinary bladder cancer, although OC can affect urination. Nor is there literature support for the cooccurrence of OC with uterus interstitial leiomyoma, hemangioma of intra-abdominal structure, submucous uterine fibroid, cervical polyps, or lymphangioma.

Tubulin Alpha Like 3 (TUBAL3) is the topmost comorbidity enriched MOA protein. Tubulin proteins are associated with breast cancer, which can co-occur with OC²⁴. There are also enriched pathways associated with ephrin ligands. Aggressive forms of ovarian cancer have been previously investigated to upregulate forms of ephrin, such as ephrinA5²⁵. There are 14 ephrin-related comorbidity enriched MOA proteins found (score > 0.05)²⁶.

We next examined a set of 11 genes associated with OC risk from a study that assessed the multiple-gene germline sequences in 95,561 women with OC into **LeMeDISCO**²⁷. The results for the top 20 comorbidities, MOA proteins, and pathways associated are shown in in Table 5. There were 207 significant comorbidities (p-value < 0.05) predicted, 2,895 comorbidity enriched MOA proteins and 5 significant pathways associated with the top ranked 100 proteins (p-value < 0.05). The top hit comorbidity associated with OC was Sertoli-Leydig cell tumor, a rare cancer of the ovaries, which can yield an increase in the male sex hormone, testosterone²⁸. Sex cord-gonadal stromal tumor is a rare type of ovarian cancer. There is some evidence for the comorbidity of diffuse scleroderma, severe acute respiratory syndrome, hyperuricemia, coronary stenosis, lymphatic system disease, germinoma,

embryonal cell carcinoma and OC. Germinoma, another comorbidity predicted to be associated with OC, is a tumor often found in the brain is typically formed due to dysfunctional localization of germ cells to their respective locations. Furthermore, hemoglobinopathy, a disease(s) of the blood, was also a comorbidity associated with OC. A study found a relationship between hemoglobin levels and interleukin-6 levels in individuals with untreated epithelial ovarian cancer, which indicated the inflammatory role in cancer-associated anemia²⁹. There is scant literature evidence for the comorbidity of adenosquamous carcinoma or acinar cell carcinoma with OC.

One of the top comorbidity enriched MOA proteins found is GMPR, also found to be up-regulated in metastatic serous papillary ovarian tumors from a differential gene expression analysis³⁰. RAB-related pathways are provided by the pathway analysis. Rab35, a protein associated with modification of actin remodeling³¹, is a top 20 comorbidity enriched MOA protein that has been shown to be upregulated in individuals with OC under androgen treatment. Notably, there was a significant overlap p-value from the GWAS driven **LeMeDISCO** results to the **MEDICASCY** MOA protein driven **LeMeDISCO** results for the predicted comorbidities (p-value = 5.3×10^{-12}) and MOA proteins (p-value < 0.0001).

LeMeDISCO web server

The **LeMeDISCO** web service allows researchers to query our library of 3,608 diseases or input a set of pathogenic human genes/proteins and compute their predicted comorbidities, MOA proteins, and pathways associated. The web service is freely available for academic users at <http://sites.gatech.edu/cssb/LeMeDISCO>.

Discussion

LeMeDISCO is a systematic approach for studying and analyzing possible features underlying the common proteins underlying a set of comorbid diseases. The resulting predicted driver proteins and pathways for each disease or input gene set can allow researchers to generate new diagnostic and

treatment options and hypotheses. Interestingly, there were some MOA proteins and pathways present across approximately a third of the diseases, implying common disease drivers. The implications of this observation and its relationship to disease origins will be pursued in future work. We do note that the current comorbid disease analysis strongly suggests that the “*one target-one disease-one molecule*” approach often used in developing disease therapeutics³² is likely somewhat too simplistic.

To fully understand the complexities of a disease, one must trace the origin of its pathogenesis, which may be due to a variant that is somehow related to the condition. However, such variants may also be associated with a disease not previously known to be associated with that condition. Such interrelations can be further investigated by identifying high confidence comorbidity predictions from **LeMeDISCO**, regardless of whether or not their comorbidity was previously known in the literature. For example, analysis of the comorbid diseases associated with CAD and OC have not only recapitulated known disease comorbidities but have also provided novel insights. The **MEDICASCY** and GWAS-driven results for CAD yielded high confidence associations between hepatic diseases and forms of anemia, which can be further investigated through the comorbidity enriched MOA proteins and pathways. Furthermore, the **MEDICASCY** and GWAS-driven results for OC revealed more high confidence associations to other forms of cancer such as thyroid gland cancer and Sertoli-Leydic cell tumor.

LeMeDISCO not only has applications to the study of the underlying etiology behind a disease but may also be used during the early stages of drug discovery to identify efficacious drugs. Rather than starting with a small molecule or protein target of choice, **LeMeDISCO** allows one to begin at the level of disease biology, often termed phenotypic drug discovery. In future work, we shall demonstrate the utility of **LeMeDISCO** in identifying efficacious drugs to treat a given disease. Overall, the results of the current analysis and preliminary applications to drug discovery suggest that **LeMeDISCO** provides a set of tools for elucidating disease etiology and interrelationships and that a more systems wide, comprehensive approach to both personalized medicine and drug discovery is required.

Acknowledgments

This project was funded by R35GM118039 of the Division of General Medical Sciences of the NIH. We thank Bartosz Ilkowski for internal computing support and Jessica Forness for proof-reading the manuscript.

Author Contributions

CA, HY and JS conceived of the method; CA and HY implemented the method, CA, HY and JS analyzed the data and wrote the paper.

Data availability

The web service is freely available for academic users at <http://sites.gatech.edu/cssb/LeMeDISCO>.

Methods

Overview of LeMeDISCO

A flowchart of **LeMeDISCO** is shown in Figure 2. **LeMeDISCO** employs **MEDICASCY**¹¹ to predict possible disease MOA proteins. Here, **MEDICASCY** is applied in prediction mode (i.e., any training drugs having a Tanimoto-Coefficient =1 to a given input drug is excluded from training) to avoid a strong bias towards drugs in the training set on a set of 2,095 FDA-approved drugs³². For each of the 3,608 indications, we rank the 2,095 probe drugs according to their Z-scores, Z_d , defined using the raw score computed by **MEDICASCY** from:

$$Z_d = \left(\frac{\text{raw score} - \text{average raw score of 2,095 drugs}}{\text{standard deviation of 2095 raw scores}} \right) \quad (1)$$

To predict a drug as having the given indication, we applied a Z_d cutoff of 1.65 that approximately corresponds to a p-value of 0.05 for the upper tailed null hypotheses of random Z_d . Thus, for each indication D, the 2,095 probe drugs are separated into two groups: N_1 are predicted to have indication D ($Z_d \geq 1.65$) and $N_2 (=2,095 - N_1)$ are not predicted to have indication D ($Z_d < 1.65$). This is a very loose prediction of a drug's indication with the advantage that it always predicts some drugs having the indication with its expected statistical confidence. Then, for a given indication D and each protein target, T, in the human proteome of our modeled 32,584 proteins, there are a subset of the drugs (or perhaps none) predicted by **FINDSITE**^{comb2.0}³³ to bind T. The relative risk $RR(D, T)$ of the given target T with respect to indication D as:

$$RR(D, T) = \frac{N_1^T / N_1}{N_2^T / N_2} \quad (2a),$$

where N_1^T and N_2^T are the numbers of drugs binding to T with and without indication D, respectively. The numerator is the estimation of the probability of drugs having the predicted indication D ($Z_d \geq 1.65$) that bind to protein T ($F1 = N_1^T / N_1$). The denominator is the probability of finding drugs that do not have the predicted indication D but which bind to protein T ($F2 = N_2^T / N_2$). This latter probability serves as the

background probability that an arbitrary drug will bind to T. When no drug is predicted to bind to protein T, $RR(D,T)$ is set to zero. $RR(D,T)=F1/F2 > 1$ means that a drug having indication D is more likely to bind to T than arbitrary drugs not having the predicted indication D will bind to T.

We then compute the statistical significance of $RR(D,T)$ by calculating a p-value using Fisher's exact test^{34,35} on the following contingency table:

$$\begin{pmatrix} N_1^T & N_1 - N_1^T \\ N_2^T & N_2 - N_2^T \end{pmatrix} \quad (2b)$$

We define a protein target T as predicted to be a possible MOA target for indication D if its p-value < 0.05 because it is more likely to be targeted by efficacious drugs than arbitrary drugs. Thus, for each of the 3,608 indications, there is a list of predicted possible MOA proteins.

To reduce false positive MOAs, we utilized the human protein atlas database (<https://www.proteinatlas.org/about/download>, *normal_tissue.tsv*) of expression profiles for proteins in normal human tissues based on immunohistochemistry using tissue micro arrays³⁶ to filter those proteins that are “not detected” and not “uncertain” in all tested tissues related to an indication. To determine the tissues related to an indication, tissues are mapped to their ICD-10 main codes and indications having the same main codes are related to the tissue.

Using the input of two sets of putative MOA proteins having a p-value of < 0.05 calculated by Fisher's exact test³⁴, we calculate their Jaccard index³⁷ $J(D_1, D_2)$ (J-score) defined in eq. 3a as

$$J\text{-score} = N_s / (N_{D1} + N_{D2} - N_s) \quad (3a)$$

We then calculate the p-value for significance by Fisher's exact test for the contingency table³⁴ that gives the probability of having overlap $\geq N_s$ by randomly selecting N_{D2} out of N_t proteins^{34,38}:

$$\begin{pmatrix} N_s & N_{D2} - N_s \\ N_{D1} & N_t - N_{D1} \end{pmatrix} \quad (3b)$$

N_{D_1} , N_{D_2} are the numbers of MOA proteins/genes of disease D_1 and D_2 ; N_s is the number of overlapped MOA proteins between D_1 , D_2 and N_t is the total number of human proteins. The Jaccard index J-score is a statistical measure of the similarity between MOA proteins of D_1 and D_2 , and its value ranges between 0 and 1. Since the null hypothesis of N_s corresponds to a hypergeometric distribution, the p-value of observing the number of overlapped MOA proteins between D_1 , $D_2 \geq N_s$ can be calculated using Fisher's exact test on the table in eq. 3b³⁵. We will use the J-score for predicting comorbidity and compare it with the observed comorbidity.

In large scale disease-disease comorbidity calculations, we use the MOAs predicted by **MEDICASCY**¹¹. In addition, MOA targets between disease pairs can also be derived from experimental data; examples include differential gene expression (GE), Mendelian or somatic mutation profiles comparing disease vs. control normal samples, better vs. worse prognosis samples, or drug treated vs. control untreated samples³⁹.

Benchmarking of LeMeDISCO

We validated **LeMeDISCO**'s J-score by correlating it with the observed comorbidity as quantified by (a) the logarithm of relative risk $\log(RR)$ score and (b) the ϕ -score (Pearson's correlation for binary variables)¹⁴. The relative risk (RR) is the probability that two diseases cooccur in a single individual relative to random. Since RR scales exponentially with respect to the strength of two interacting diseases, we use $\log(RR)$ for correlation analysis. The $\log(RR)$ and ϕ -score are computed from US Medicare insurance claim data using¹⁴:

$$\log(RR) = \log\left(\frac{n_{AB}/n_{tot}}{(n_A/n_{tot})(n_B/n_{tot})}\right) \quad (4a)$$

$$\phi - \text{score} = (n_{AB} * n_{tot} - n_A * n_B) / \sqrt{n_A * n_B * (n_{tot} - n_A) * (n_{tot} - n_B)} \quad (4b)$$

where n_{tot} = total number of patients; n_A , n_B = number of patients diagnosed with disease A and B, and n_{AB} = number of patients diagnosed with both diseases A and B.

Identification of key MOA proteins and associated pathways for disease comorbidity

After determining the significant comorbidities for each disease, the p-value weighted frequency of shared MOA proteins across the top 100 predicted comorbidities are calculated. We define a p-value weighted frequency of an input MOA as follows (i.e. CoMOAenrich score): If MOA protein T is shared by a comorbid indication D and the p-value of T associated with D is P , then the weight defined by the $\min(1.0, -\alpha \log P)$ is counted as T's frequency. In practice, we used 10 cancer cell line data⁴⁰ to optimize the coefficient α to 0.025. We further computed a p-value via $e^{-\frac{\text{CoMOAenrich score}}{\alpha}}$ where $\alpha = 0.025$, as previously mentioned. These MOA proteins expand the number of possible molecular players driving disease pathogenesis. An empirically derived CoMOAenrich score (normalized by the number of comorbid indications that is 100) threshold of 0.01 was used, which is equivalent to 1% of the comorbid indications having the MOA proteins with a significant p-value ($< 4.2 \times 10^{-18}$). Then, up to the top 100 comorbidity enriched MOA proteins for each disease were used in global pathway analysis via Reactome¹². The pathways with a p-value < 0.05 were extracted. The frequency of pathways across diseases was assessed to identify common pathways of disease.

LeMeDISCO usage

As shown in Figure 2, **LeMeDISCO** can be used in two different ways: 1.) **MEDICASCY-driven LeMeDISCO**: The comorbidities for any of the 3,608 diseases from the **MEDICASCY** provided MOA proteins are predicted (Figure 2A). 2.) **Pathogenic gene set driven LeMeDISCO**: Input your own pathogenic gene set derived from differential gene expression, GWAS, exome analysis, or other experimental/clinical techniques (shown in Figure 2B). The **LeMeDISCO** web service allows users to query the **LeMeDISCO** database as well as input their own set of pathogenic genes to assess the associated comorbidities, MOA proteins, and pathways.

References

- 1 Somers, E. C., Thomas, S. L., Smeeth, L. & Hall, A. J. Are individuals with an autoimmune disease at higher risk of a second autoimmune disorder? *Am J Epidemiol* **169**, 749-755, doi:10.1093/aje/kwn408 (2009).
- 2 Cramer, A., Waldorp, L., van der Maas, H. & Borsboom, D. Comorbidity: a network perspective. *The Behavioral and brain sciences* **33**, 137-150 (2010).
- 3 Melamed, R. D., Emmett, K. J. & Madubata, C. Genetic similarity between cancers and comorbid Mendelian diseases identifies candidate driver genes. *Nature Communications* **6**, 7033 (2015).
- 4 Lee, D.-S. *et al.* The implications of human metabolic network topology for disease comorbidity. *Proceedings of the National Academy of Sciences of the United States of America* **105**, 9880-9885 (2008).
- 5 Zhou, X., Menche, J., Barabási, A.-L. & Sharma, A. Human symptoms–disease network. *Nature Communications* **5**, 4212 (2014).
- 6 Menche, J. *et al.* Disease networks. Uncovering disease-disease relationships through the incomplete interactome. *Science* **347**, 1257601 (2015).
- 7 Ko, Y., Cho, M., Lee, J.-S. & Kim, J. Identification of disease comorbidity through hidden molecular mechanisms. *Scientific Reports* **6**, 39433 (2016).
- 8 Guo, M. *et al.* Analysis of disease comorbidity patterns in a large-scale China population. *BMC Medical Genomics* **12**, 177 (2019).
- 9 Erin M Ramos *et al.* Phenotype–Genotype Integrator (PheGenI): synthesizing genome-wide association study (GWAS) data with existing genomic resources. *European Journal of Human Genetics* **22**, 144-147 (2014).
- 10 Schriml, L. *et al.* Disease Ontology: a backbone for disease semantic integration. *Nucleic Acids Res.* **40**, D940-D946 (2012).
- 11 Zhou, H. *et al.* MEDICASCY: A Machine Learning Approach for Predicting Small Molecule Drug Side Effects, Indications, Efficacy and Mode of Action. *Submitted* (2020).
- 12 Jassal, B. *et al.* The reactome pathway knowledgebase. *Nucleic Acids Res* **48**, D498-d503, doi:10.1093/nar/gkz1031 (2020).
- 13 Tanimoto, T. T. An Elementary Mathematical Theory of Classification and Prediction. *IBM Interanl Report* (1958).
- 14 Hidalgo, C. A., Blumm, N., Barabasi, A. L. & Christakis, N. A. A dynamic network approach for the study of human phenotypes. *PLoS computational biology* **5**, e1000353 (2009).
- 15 Rogers, F. B. Medical subject headings. *Bull Med Libr Assoc* **51**, 114-116 (1963).
- 16 Schriml, L. M. *et al.* Human Disease Ontology 2018 update: classification, content and workflow expansion. *Nucleic Acids Res* **47**, D955-D962, doi:10.1093/nar/gky1032 (2019).
- 17 Fuster, V., Badimon, L., Badimon, J. J. & Chesebro, J. H. The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes. *New England Journal of Medicine* **326**, 310-318, doi:10.1056/NEJM199201303260506 (1992).
- 18 Falk, J. A. *et al.* Cardiac disease in chronic obstructive pulmonary disease. *Proc Am Thorac Soc* **5**, 543-548, doi:10.1513/pats.200708-142ET (2008).
- 19 Wang, L., Gao, S., Yu, M., Sheng, Z. & Tan, W. Association of asthma with coronary heart disease: A meta analysis of 11 trials. *PloS one* **12**, e0179335-e0179335, doi:10.1371/journal.pone.0179335 (2017).
- 20 Zhu, L., Zhang, Y., Guo, Z. & Wang, M. Cardiovascular Biology of Prostanoids and Drug Discovery. *Arterioscler Thromb Vasc Biol* **40**, 1454-1463, doi:10.1161/atvbaha.119.313234 (2020).
- 21 van der Harst, P. & Verweij, N. Identification of 64 Novel Genetic Loci Provides an Expanded View on the Genetic Architecture of Coronary Artery Disease. *Circulation Research* **122**, 433-443, doi:10.1161/CIRCRESAHA.117.312086 (2018).

- 22 Zandparsa, A., Habashizadeh, M., Moradi Farsani, E., Jabbari, M. & Rezaei, R. Relationship between Renal Artery Stenosis and Severity of Coronary Artery Disease in Patients with Coronary Atherosclerotic Disease. *Int Cardiovasc Res J* **6**, 84-87 (2012).
- 23 Caporali, A. & Emanuelli, C. Cardiovascular actions of neurotrophins. *Physiological reviews* **89**, 279-308, doi:10.1152/physrev.00007.2008 (2009).
- 24 Nami, B. & Wang, Z. Genetics and Expression Profile of the Tubulin Gene Superfamily in Breast Cancer Subtypes and Its Relation to Taxane Resistance. *Cancers (Basel)* **10**, 274, doi:10.3390/cancers10080274 (2018).
- 25 Jukonen, J. *et al.* Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality. *Scientific Reports* **11**, 8856, doi:10.1038/s41598-021-88382-6 (2021).
- 26 Śliwa, A. *et al.* Regulation of human chorionic gonadotropin beta subunit expression in ovarian cancer. *BMC Cancer* **19**, 746, doi:10.1186/s12885-019-5960-2 (2019).
- 27 Kurian, A. W. *et al.* Association of ovarian cancer (OC) risk with mutations detected by multiple-gene germline sequencing in 95,561 women. *Journal of Clinical Oncology* **34**, 5510-5510, doi:10.1200/JCO.2016.34.15_suppl.5510 (2016).
- 28 Tandon, R., Goel, P., Saha, P. K., Takkar, N. & Punia, R. P. S. A rare ovarian tumor - Sertoli-Leydig cell tumor with heterologous element. *MedGenMed* **9**, 44-44 (2007).
- 29 Macciò, A. *et al.* Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. *Blood* **106**, 362-367, doi:10.1182/blood-2005-01-0160 (2005).
- 30 Bignotti, E. *et al.* Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. *Am J Obstet Gynecol* **196**, 245.e241-211, doi:10.1016/j.ajog.2006.10.874 (2007).
- 31 Villagomez, F. R., Medina-Contreras, O., Cerna-Cortes, J. F. & Patino-Lopez, G. The role of the oncogenic Rab35 in cancer invasion, metastasis, and immune evasion, especially in leukemia. *Small GTPases* **11**, 334-345, doi:10.1080/21541248.2018.1463895 (2020).
- 32 Wishart, D. S. *et al.* DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic Acids Res* **46**, D1074-D1082, doi:10.1093/nar/gkx1037 (2018).
- 33 Zhou, H., Cao, H. & Skolnick, J. FINDSITE^{comb2.0}: A New Approach for Virtual Ligand Screening of Proteins and Virtual Target Screening of Biomolecules. *Journal of Chemical Information and Modeling* **58**, 2343-2354 (2018).
- 34 Fisher, R. A. On the Interpretation of χ^2 from Contingency Tables, and the Calculation of P. *Journal of the Royal Statistical Society* **85**, 87-94 (1922).
- 35 Mehta, C. R. & Patel, N. R. ALGORITHM 643: FEXACT: a FORTRAN subroutine for Fisher's exact test on unordered $r \times c$ contingency tables. *ACM Transactions on Mathematical Software* **12**, 154-161 (1986).
- 36 Uhlén, M. *et al.* Tissue-based map of the human proteome. *Science* **347**, 1260419, doi:10.1126/science.1260419 (2015).
- 37 Jaccard, P. THE DISTRIBUTION OF THE FLORA IN THE ALPINE ZONE. *New Phytologist* **11**, 37-50 (1912).
- 38 Goeman, J. J. & Bühlmann, P. Analyzing gene expression data in terms of gene sets: methodological issues. *Bioinformatics* **23**, 980-987, doi:10.1093/bioinformatics/btm051 (2007).
- 39 Hintzsche, J. D., Robinson, W. A. & Tan, A. C. A Survey of Computational Tools to Analyze and Interpret Whole Exome Sequencing Data. *International Journal of Genomics* **2016**, 7983236, doi:10.1155/2016/7983236 (2016).
- 40 NCI-60 Human Tumor Cell Lines Screen. https://dtp.cancer.gov/discovery_development/nci-60/

Figures

Figure 1. **A.** ICD-10 main classification coverage across the 3,608 diseases. Some diseases are found in multiple groups; they were counted in each group for which they are associated. **B.** Histogram of the number of MOAs. **C.** Frequency and density of the J-score for the ~3 million significant (p -value < 0.05), non-redundant disease pairs. **D.** Frequency and density of the degree (number of edges) of each disease

(node). **E.** Fraction of diseases in the giant component of disease-disease network versus the J-score cutoff.

A

B

Figure 2. LeMeDISCO schematic representation of (A) the method for determining the MOA proteins associated with a disease indication via **MEDICASCY**, and (B) the method for determining the comorbidities associated with a given disease and its molecular mechanisms via LeMeDISCO.

Tables

Table 1. Comparison of LeMeDISCO's J-score with the XD score, NG, S_{AB} score and symptom similarity for correlations with comorbidity quantified by the log(RR) score, ϕ -score and recall^a.

	Unbinned ^b		10 bins ^b		Recall
	Log(RR) score	ϕ -score	Log(RR) score	ϕ -score	
198,149 disease pairs ^c					
LeMeDISCO	0.312(0.0)	0.218(0.0)	0.933(8.1x10⁻⁵)	0.900(3.9x10⁻⁴)	49.7%
29,783 pairs ^d					
LeMeDISCO	0.185(0.0)	0.138(0.0)	0.939(5.6x10⁻⁵)	0.829(3.0x10⁻³)	56.0%
XD score ⁷	0.050(5.9x10 ⁻¹⁸)	0.082(0.0)	0.445(0.20)	0.252(0.48)	6.5%
NG ^e	0.008(0.17)	0.058(1.3x10 ⁻²³)	-0.436	-0.175	-
947 disease pairs ^f					
LeMeDISCO	0.217(1.5x10⁻¹¹)	0.282(9.0x10⁻¹⁹)	0.682(0.030)	0.688(0.028)	75.8%
S_{AB} score ⁶	-0.188(5.5x10 ⁻⁹)	-0.218(1.2x10 ⁻¹¹)	-0.671(0.034)	-0.473(0.17)	8.5%
2,630 disease pairs ^g					
LeMeDISCO	0.184(1.9x10 ⁻²¹)	0.196(3.5x10⁻²⁴)	0.774(8.6x10 ⁻³)	0.654(0.040)	71.1%
Symptom similarity ⁵	0.337(0.0)	0.197(1.6x10⁻²⁴)	0.950(2.6x10⁻⁵)	0.960(1.1x10⁻⁵)	100%

^a Numbers in parentheses are the p-values of the corresponding correlation. Bold indicates the best results for the given data set.

^b Unbinned means raw data; each pair is a data point. 10 bins: partitioning the prediction scores into 10 equal size bins. In each bin, the log(RR) & ϕ -score are averaged over data points in the bin. This gives equal weight to the rare prediction scores in the correlation analysis.

^c Mapping the DOID IDs from the human DO database to ICD9 IDs of Ref.¹⁴, gives a set of 198,149 disease pairs

^d Mapped the ICD9 disease code to our DOID of DO and obtained a consensus subset of 29,783 disease pairs from Table 1's dataset of 97,665 disease pairs in Ref.⁷.

^e NG is the number of shared genes between disease pairs in Ref.⁷.

^f Consensus set of 947 disease pairs from the dataset of Ref.⁶ and our dataset of 198,149.

^g A consensus dataset of 2,630 disease pairs was obtained from their Supplementary dataset 4 of Ref.⁵ compared to our set of 198,149 pairs.

Table 2. Top 20 comorbidities (excluding same disease pair, (i.e. CAD-CAD)), top 20 comorbidity enriched MOA proteins (with respect to original disease), and top 20 (max) pathways associated with the prediction CAD results.

Comorbidities			MOA proteins		Pathways		
Disease	J -score	p-value	Gene name	Score	Pathway	Top pathway	p-value
Cardiovascular system disease	0.49	< 0.0001	OSBPL8	0.38	Nuclear Receptor transcription pathway	Gene expression (Transcription)	4.60x10 ⁻¹⁴
Myocardial infarction	0.46	< 0.0001	NR4A3	0.38	SUMOylation of intracellular receptors	Metabolism of proteins	0.01
Heart disease	0.45	< 0.0001	LXN	0.38	Prostanoid ligand receptors	Signal transduction	0.01
Kidney disease	0.44	< 0.0001	SLC8A3	0.38	Synthesis of very long-chain fatty acyl-CoAs	Metabolism	0.03
Diabetes mellitus	0.44	< 0.0001	KCNA10	0.37	Noncanonical activation of NOTCH3	Signal transduction	0.03
Familial hyperlipidemia	0.4	< 0.0001	NR3C2	0.37	PP2A-mediated dephosphorylation of key metabolic factors	Metabolism	0.04
Congestive heart failure	0.36	< 0.0001	OSBPL5	0.37	E2F mediated regulation of DNA replication	Cell cycle	0.05
Obstructive lung disease	0.35	< 0.0001	RARRES1	0.37			
Hepatorenal syndrome	0.34	< 0.0001	COX7A2	0.36			
Alzheimer's disease	0.34	< 0.0001	COX7A2L	0.36			
Syndrome	0.34	< 0.0001	COX7A1	0.36			

Glucose intolerance	0.33	< 0.0001	GRP	0.36			
Asthma	0.33	< 0.0001	TSPAN13	0.36			
Proteinuria	0.32	< 0.0001	ELOVL7	0.36			
Atherosclerosis	0.32	< 0.0001	PLEKHG4	0.35			
Alport syndrome	0.32	< 0.0001	HRASLS5	0.35			
Glomerulonephritis	0.32	< 0.0001	PLA2G16	0.35			
Liver disease	0.31	< 0.0001	ELOVL1	0.34			
Mitral valve insufficiency	0.31	< 0.0001	RARRES3	0.34			
IgA glomerulonephritis	0.31	< 0.0001	NR3C1	0.34			

Table 3. Top 20 comorbidities, top 20 comorbidity enriched MOA proteins (with respect to original disease), and top 20 (max) pathways associated with the prediction CAD GWAS-driven LeMeDISCO results using the gene set from ²¹.

Comorbidities			MOA proteins		Pathways		
Disease	J-score	p-value	Gene name	Score	Pathway	Top pathway	p-value
Anuria	0.04	< 0.0001	ZMYM6	0.09	ERBB2 Activates PTK6 Signaling	Signal transduction	7.10x10 ⁻⁶
Renal artery disease	0.03	1.10E-10	TARBP2	0.08	ERBB2 Regulates Cell Motility	Signal transduction	9.60x10 ⁻⁶
Skin hemangioma	0.02	2.75E-05	AFTPH	0.08	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Signal transduction	0.0001
Leukopenia	0.02	0.0001	MRPS12	0.08	Signaling by ERBB2 TMD/JMD mutants	Disease	0.0001
Plasma cell neoplasm	0.02	0.0002	SYNM	0.08	Negative regulation of the PI3K/AKT network	Signal transduction	0.0002
Leukocyte disease	0.02	0.0008	EHBP1	0.07	GRB2 events in ERBB2 signaling	Signal transduction	0.0002
Hereditary hemorrhagic telangiectasia	0.02	0.002	SGOL1	0.07	PI3K events in ERBB2 signaling	Signal transduction	0.0002
Dilated cardiomyopathy	0.02	0.003	AFF2	0.07	Signaling by ERBB2 KD Mutants	Disease	0.0003
Xeroderma pigmentosum	0.01	0.003	CLSTN3	0.07	Signaling by ERBB2 in Cancer	Disease	0.0003
Recurrent hypersomnia	0.01	0.003	CD248	0.07	Downregulation of ERBB2 signaling	Signal transduction	0.0003
Lactic acidosis	0.01	0.005	LRRCC1	0.07	SHC1 events in ERBB2 signaling	Signal transduction	0.0003

Gastric antral vascular ectasia	0.01	0.007	PRICKLE3	0.07	Constitutive Signaling by Aberrant PI3K in Cancer	Disease	0.0008
POEMS syndrome	0.01	0.006	MDFIC	0.07	TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	Gene expression (Transcription)	0.002
Hemoglobin D disease	0.01	0.006	PCDH7	0.07	Activation of TRKA receptors	Signal transduction	0.002
Hereditary spherocytosis	0.01	0.006	MOB3C	0.07	Downregulation of ERBB4 signaling	Signal transduction	0.003
Myelophthisic anemia	0.01	0.006	LOC101060321	0.07	PI3K/AKT Signaling in Cancer	Disease	0.004
Protein-deficiency anemia	0.01	0.006	FAM8A1	0.07	TRKA activation by NGF	Signal transduction	0.007
Hemolytic-uremic syndrome	0.01	0.006	LRRC17	0.06	Signaling by ERBB2	Signal transduction	0.007
Shwachman-Diamond syndrome	0.01	0.006	LRRTM2	0.06	Signaling by Non-Receptor Tyrosine Kinases	Signal transduction	0.009
Favism	0.01	0.006	DISC1	0.06	Signaling by PTK6	Signal transduction	0.009

Table 4. Top 20 comorbidities (excluding same disease pair, (i.e. OC-OC)), top 20 comorbidity enriched MOA proteins (with respect to original disease), and top 20 (max) pathways associated with the prediction OC results.

Comorbidities			MOA proteins		Pathways		
Disease	J-score	p-value	Gene name	Score	Pathway	Top pathway	p-value
Thyroid gland cancer	0.68	< 0.0001	TUBAL3	0.37	ERBB2 Activates PTK6 Signaling	Signal transduction	1.8x10 ⁻⁵
Rectum cancer	0.66	< 0.0001	GPRC5A	0.31	ERBB2 Regulates Cell Motility	Signal transduction	2.51x 10 ⁻⁵
Esophageal cancer	0.65	< 0.0001	OR4S1	0.31	TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	Gene expression (Transcription)	4.36x10 ⁻⁵
Pancreatic cancer	0.64	< 0.0001	TUBA4A	0.3	EPH-Ephrin signaling	Developmental biology	0.0002
Lung cancer	0.63	< 0.0001	TECR	0.29	EPH-ephrin mediated repulsion of cells	Developmental biology	0.0003
Stomach cancer	0.61	< 0.0001	SRD5A1	0.29	Signaling by ERBB2 TMD/JMD mutants	Disease	0.0003
Fallopian tube cancer	0.55	< 0.0001	EGFLAM	0.28	GRB2 events in ERBB2 signaling	Signal transduction	0.0004
Urinary bladder cancer	0.54	< 0.0001	OR6C6	0.28	PI3K events in ERBB2 signaling	Signal transduction	0.0005
Liver cancer	0.54	< 0.0001	TUBB1	0.28	Signaling by ERBB2 KD Mutants	Disease	0.0007
Peritoneum cancer	0.54	< 0.0001	CHDC2	0.28	Signaling by ERBB2 in Cancer	Disease	0.0008

Colon cancer	0.5	< 0.0001	OR5B12	0.27	Downregulation of ERBB2 signaling	Signal transduction	0.0008
Bile duct cancer	0.5	< 0.0001	OR6C70	0.26	SHC1 events in ERBB2 signaling	Signal transduction	0.0008
Sarcoma	0.48	< 0.0001	OR2T33	0.26	VEGF binds to VEGFR leading to receptor dimerization	Signal transduction	0.002
Uterus interstitial leiomyoma	0.48	< 0.0001	SRD5A3	0.26	VEGF ligand-receptor interactions	Signal transduction	0.002
Hemangioma of intra-abdominal structure	0.48	< 0.0001	DSTYK	0.26	EPHA-mediated growth cone collapse	Developmental biology	0.003
Intracranial structure hemangioma	0.48	< 0.0001	OR2A2	0.26	Activation of TRKA receptors	Signal transduction	0.003
Submucous uterine fibroid	0.48	< 0.0001	OR2A14	0.25	Microbial modulation of RIPK1-mediated regulated necrosis	Programmed cell death	0.003
Cervical polyp	0.48	< 0.0001	OR5D13	0.25	EPHB-mediated forward signaling	Developmental biology	0.004
Subserous uterine fluid	0.48	< 0.0001	EGFR	0.25	Downregulation of ERBB4 signaling	Signal transduction	0.004
Lymphangioma	0.48	< 0.0001	GPRC5B	0.25	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	Gene expression (Transcription)	0.004

Table 5. Top 20 comorbidities, top 20 comorbidity enriched MOA proteins (with respect to original disease), and top 20 (max) pathways associated with the prediction OC GWAS driven results using the gene set from ²⁷.

Comorbidities			MOA proteins		Pathways		
Disease	J-score	p-value	Gene name	Score	Pathway	Top pathway	p-value
Sertoli-Leydig cell tumor	0.004	7.11E-05	GMPR	0.23	RAB geranylgeranylation	Metabolism of proteins	7.88x10 ⁻⁸
Sex cord-gonadal stromal tumor	0.004	7.11E-05	TUBE1	0.23	RAB regulation of trafficking	Vesicle-mediated transport	0.003
Diffuse scleroderma	0.004	2.59E-05	NTPCR	0.23	RAB GEFs exchange GTP for GDP on RABs	Vesicle-mediated transport	0.005
Severe acute respiratory syndrome	0.004	2.65E-05	AK4	0.23	Interconversion of nucleotide di- and triphosphates	Metabolism	0.008
Hyperuricemia	0.004	3.82E-05	AK2	0.23	TBC/RABGAPs	Vesicle-mediated transport	0.01
Coronary stenosis	0.004	1.31E-05	ASMTL	0.23			
Lymphatic system disease	0.004	0.0006	RAB35	0.23			
Adenosquamous carcinoma	0.003	7.95E-05	AK6	0.22			
Germinoma	0.003	0.002	TUBD1	0.22			
Hemoglobinopathy	0.003	2.73E-05	OAS2	0.22			
Genetic disease	0.003	3.11E-05	RRM1	0.22			
Embryonal cell carcinoma	0.003	0.0003	TUT1	0.22			
Acinar cell carcinoma	0.003	0.0003	IDNK	0.22			

Inflammatory breast carcinoma	0.003	0.0001	ARL13B	0.22			
Biliary tract disease	0.003	0.0004	SMG9	0.22			
Fanconi anemia	0.003	4.14E-05	ARL5A	0.22			
Ovarian carcinoma	0.003	0.0004	ERG	0.22			
Uveal cancer	0.003	1.39E-05	GTPBP8	0.22			
Carcinosarcoma	0.003	0.0002	GIMAP8	0.22			
Salivary gland adenoid cystic carcinoma	0.003	0.0005	GNL3	0.22			